SAR342434
Total Payments
$24,626
Transactions
26
Doctors
6
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $24,626 | 26 | 6 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12,754 | 19 | 51.8% |
| Consulting Fee | $11,872 | 7 | 48.2% |
Payments by Type
Research
$12,754
19 transactions
General
$11,872
7 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine | SANOFI-AVENTIS U.S. LLC | $5,807 | 2 |
| LISA Pump | SANOFI-AVENTIS U.S. LLC | $4,323 | 2 |
| Six-Month, Randomized, Open-Label, Parallel-group Comparison of SAR342434 to Humalog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine, With a 6-month Safety Extension Period | SANOFI-AVENTIS U.S. LLC | $1,617 | 1 |
| A Randomized, 2X4 Week, Active-Controlled, Open-Label, 2-Treatment Arm, 2-Period Cross-Over Study Assessing the Safety of SAR342434 and Humalog? Used in Continuous Subcutaneous Insulin Infusion (CSII | SANOFI-AVENTIS U.S. LLC | $1,007 | 2 |
Top Doctors Receiving Payments for SAR342434
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Endocrinology, Diabetes & Metabolism | Aurora, CO | $6,081 | 10 |
| , M.D | Specialist | Phoenix, AZ | $5,480 | 3 |
| , M.D | Internal Medicine | Coconut Creek, FL | $5,480 | 3 |
| , M.D | Specialist | Escondido, CA | $4,009 | 5 |
| , M.D | Endocrinology, Diabetes & Metabolism | Little Rock, AR | $2,665 | 4 |
| , M.D | Internal Medicine | San Diego, CA | $912.20 | 1 |
Ad
Manufacturing Companies
- SANOFI-AVENTIS U.S. LLC $24,626
Product Information
- Type Drug
- Total Payments $24,626
- Total Doctors 6
- Transactions 26
About SAR342434
SAR342434 is a drug associated with $24,626 in payments to 6 healthcare providers, recorded across 26 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI-AVENTIS U.S. LLC.
Payment data is available from 2017 to 2017. In 2017, $24,626 was paid across 26 transactions to 6 doctors.
The most common payment nature for SAR342434 is "Unspecified" ($12,754, 51.8% of total).
SAR342434 is associated with 4 research studies, including "Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine" ($5,807).